CONTRACEPTIVE CHOICE FOR WOMEN WITH RISK-FACTORS

被引：4

作者：

FRASER, IS

机构：

[1] Department of Obstetrics and Gynaecology, The University of Sydney, Sydney, New South Wales

来源：

DRUG SAFETY | 1993年 / 8卷 / 04期

关键词：

D O I：

10.2165/00002018-199308040-00002

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Women with many medical conditions need to plan their families with special care. For such women, the risk of complications with particular contraceptive methods is increased. Women with severe hypertension, a previous myocardial infarction or venous thromboembolism, or cerebrovascular stroke have a significant risk of problems in pregnancy, and should avoid the combined pill. The combined pill may increase the risk of cardiovascular disease in patients with diabetes mellitus and may worsen the severity of migrainous headaches in susceptible patients. Women with active hepatitis should wait for liver function tests to normalise before becoming pregnant or starting the combined pill or injectable progestogen. Control of epilepsy may deteriorate with use of the combined pill; this is probably because of the risk of drug interactions. Similarly, contraceptive control may also fail in women receiving rifampicin (rifampin) concurrently with contraceptive steroids. Intrauterine contraceptive devices should not be used in women who have experienced previous episodes of pelvic inflammatory disease, or with previous malignancy of the genital tract until complete cure is likely. Other conditions which may appear. become more common or worsen when the combined pill is prescribed include hepatic adenoma, gall bladder disease, ulcerative colitis, alopecia, hirsutism and acne. Some of these conditions are potentially hazardous to the woman's health, in which case combined pill use should be stopped. If the condition is unchanged then the combined pill may sometimes be reintroduced with caution.

引用

页码：271 / 279

页数：9

共 19 条

[1]

Filshie M., Guillebaud J., Contraception — science and practice, (1991)

[2]

Fraser I.S., Systemic hormonal contraception by non-oral roots, Contraception — science and practice, pp. 109-125, (1989)

[3]

Fraser I.S., Weisberg E., A comprehensive review of injectable contraception with special emphasis on depot medroxyprogesterone acetate, Medical Journal of Australia, 1, pp. 1-19, (1981)

[4]

Gillmer M.D.G., Metabolic effects of combined oral contraceptives, Contraception — science and practice, pp. 11-38, (1989)

[5]

Guillebaud J., Practical prescribing of the combined oral contraceptive pill, Contraception — science and practice, pp. 69-93, (1989)

[6]

Gomel V., Microsurgical reversal of female sterilisation: a reappraisal, Fertility and Sterility, 33, (1980)

[7]

Guillebaud J., The pill, (1987)

[8]

Harlap S., Kost K., Forrest J.D., Preventing pregnancy, protecting health: a new look at birth control choices in the United States, (1991)

[9]

Hull M.G.R., Gordon C., Beard R.W., Organisation and results of a pregnancy termination service in a National Health Service hospital, Journal of Obstetrics and Gynaecology of the British Commonwealth, 81, pp. 173-181, (1974)

[10]

Kelaghan J., Rubin G.L., Ory H.W., Layde P.M., Barrier-method contraceptives and pelvic inflammatory disease, Journal of the American Medical Association, 248, (1982)

← 1 2 →